OMERS Administration Corp’s Myriad Genetics MYGN Stock Holding History

OMERS Administration Corp’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-30,100	Closed	-$1.39M	–	288
2018 Q3	$1.39M	Buy	+30,100	New	+$1.34M	0.01%	253
2014 Q3	–	Sell	-11,000	Closed	-$428K	–	399
2014 Q2	$428K	Sell	11,000 -12,800	-54%	-$476K	0.01%	332
2014 Q1	$814K	Buy	+23,800	New	+$737K	0.03%	236

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OMERS Administration Corp's MYGN Position: Q4 2018 in Review

OMERS Administration Corp sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 30,100 shares — an estimated $1.39M sold.

OMERS Administration Corp first reported a position in MYGN in Q1 2014 and held it in 3 quarters. The position peaked at $1.39M in Q3 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

OMERS Administration Corp reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
OMERS Administration Corp sold 30,100 Myriad Genetics shares in Q4 2018, an estimated $1.39M.
OMERS Administration Corp first reported a position in Myriad Genetics in Q1 2014 and held it in 3 quarters.
OMERS Administration Corp's Myriad Genetics position peaked at $1.39M in Q3 2018.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on OMERS Administration Corp's 13F filing for Q4 2018, filed 14 Feb 2019.